Aliri

Gain valuable insights to evaluate your drug discovery program as experts share bioanalytical strategies that enable fast and flexible decision making. Don’t miss the opportunity to accelerate your research goals.

https://www.pharmtech.com/pt_w/bioanalytical-discovery

In the dynamic and competitive drug development landscape, the role of discovery has proven to be a vital component for advancing therapies within a timely and cost-efficient manner. When navigating drug discovery, it is critical to strategically balance project timelines and investments, and to select a reliable bioanalysis partner who is fully dedicated to the success of your program. Aliri’s ability to provide technical expertise and quick turnarounds will enable you to select your drug candidate and move on to the next phase of your project with ease and efficiency. Learn how discovery plays an instrumental role in expediting the drug discovery process.

Advancements in bioanalysis: explore strategic techniques used to quantify drug compounds during the discovery process.

Streamlined workflows: learn how Aliri’s workflows enable fast and flexible decision-making and keep lead times down to 6-8 weeks.

Navigating challenges: understand the complexities faced during the discovery phase and explore strategies to overcome these potential obstacles.

From discovery to GLP: learn how to advance molecules with ease and precision.


M.S., Manager of Laboratory Operations
Aliri Bioanalysis

Ryan Adler is the Manager of Laboratory Operations for Aliri Bioanalysis in Salt Lake City (formerly Pyxant Labs, Covance, Tandem Labs) where he oversees the sample analysis, validation, discovery, and quality control teams. Ryan obtained his B.S. in chemistry from Ithaca College, his M.S. in organic chemistry from The University of Utah and has over 18 years of experience in the bioanalytical industry. During his career, Ryan has held many positions, including roles in lab operations, discovery, method development and as a Principal Investigator. Ryan has extensive experience with all study types, from early-phase discovery through clinical, and working with multiple matrices, including a large variety of tissues.




M.S., Senior Director of R&D, Mass Spectrometry and Systems Validation
Aliri Bioanalysis

Edward Brewer joined Aliri Bioanalysis (formerly Pyxant Labs, Covance, Tandem Labs) in August 2016 and currently leads the non-GLP programs. He joined Tandem Labs in 1999 and led laboratory operations for both discovery and GLP groups at the Tandem Labs New Jersey facility. Ed has been involved in bioanalytical mass spectrometry since receiving his master’s degree in 1986, and his expertise comes from experience within forensic toxicology, large pharmaceutical companies, and contract research organizations. Ed’s research interests involve quantitation of pharmaceutical based products from biological matrices with high throughput assays.

Webcasts

Webinar Date/Time: Wed, Oct 11, 2023 11:00 AM EDT 

Aliri

Articles